Anbio Biotechnology is making significant strides in the European healthcare landscape with the introduction of its AF-100 C, a compact fluorescent immunoassay analyser at the forefront of point-of-care diagnostic innovation. The AF-100 C, which boasts a suite of over 70 assays, is engineered to substantially improve the efficiency of healthcare practitioners across the EU, thereby enhancing patient diagnosis and care.
In its continued effort to broaden its influence within the European Union, Anbio Biotechnology (Anbio), a trailblazer in the international in vitro diagnostics market, is proud to unveil its “Point of Care” product collection to the EU. This introduction marks a crucial development for Anbio, forging new alliances with EU distributors and medical entities, and affirming the company’s dedication to arming the EU with cutting-edge diagnostic solutions.
Anbio has evolved from its origins as a producer of Covid test kits to a versatile innovator and manufacturer of a diverse array of diagnostic equipment. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” stated Michael Lau, CEO of Anbio.
Innovative Analyzer Arms Clinicians with Over 70 Vital Tests
Anbio’s launch into the EU is anchored by the AF-100 C analyzer, an advanced, single-channel, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This potent instrument, accompanied by over 70 CE-marked assays for a wide spectrum of analytes including inflammation markers, diabetes, cancer markers, hormones, enzymes, and infectious diseases, is set to significantly revamp the EU’s clinical diagnostics framework.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau reiterated. Despite its compact stature, the AF-100 C is designed for high throughput, making it versatile for use in various healthcare settings, from specialised clinics to busy emergency wards. Its straightforward interface and robust battery, capable of supporting up to 8 hours of continuous testing, enable healthcare professionals to provide superior patient care with remarkable efficiency and accuracy.
Swift and Precise Diagnostics Promise to Enhance Patient Healthcare Experience
The broad FIA range from Anbio, capable of delivering results quickly within 3 to 15 minutes, marks a significant stride in diagnostic technology. With reagents designed with RFID chip technology for accuracy and capable of remaining stable at ambient temperature for up to 24 months, Anbio is equipped to address the urgent needs of the European healthcare sector.
As Anbio Biotechnology ventures into the EU market, it invites distributors and healthcare practitioners to explore its innovative diagnostic technologies. Dedicated to enhancing patient care through affordable, accurate, and reliable diagnostics, Anbio looks forward to forging partnerships with healthcare professionals across the EU.
